<DOC>
	<DOCNO>NCT02756858</DOCNO>
	<brief_summary>This open label extension study design provide continued access ANAVEX 2-73 eligible subject mild moderate Alzheimer 's Disease previously participate Anavex sponsor study ANAVEX2-73-002 .</brief_summary>
	<brief_title>An Extension Study ANAVEX2-73 Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Previous exposure ANAVEX273 via participation Phase 2a Study ANAVEX273 AdaptiveTrialDesign With Repeated Doses , MTD Finding , Pharmacodynamic Bioavailability Evaluation Patients With Mild Moderate Alzheimer 's Disease With 12Month Open Label FollowUp Period ( ANAVEX273002 ) Have previously participate Phase 2a Study ANAVEX273 AdaptiveTrialDesign With Repeated Doses , MTD Finding , Pharmacodynamic Bioavailability Evaluation Patients With Mild Moderate Alzheimer 's Disease With 12Month Open Label FollowUp Period ( ANAVEX273002 )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>